SPOTLIGHT: Talabostat heads to Phase III

Point Therapeutics says it will push Talabostat for pancreatic cancer into Phase III after a mid-stage trial produced encouraging data. No unexpected toxicities were recorded in Phase II that would prevent advancement of the drug, says Point, which saw its stock jump on the news. Report

Suggested Articles

Novo is working on a once-weekly basal insulin that could cut down on injections for people with Type 2 diabetes, and the phase 2 data look promising.

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.